Stock 4886 ASKA PHARMACEUTICAL HOLDINGS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-14 am EDT 		5-day change 1st Jan Change
2,399 JPY +5.13% Intraday chart for ASKA Pharmaceutical Holdings Co.,Ltd. +6.91% +34.47%
2023 Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
2023 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. Stock ASKA Pharmaceutical Holdings Co.,Ltd.
+34.47% 412M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 795B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.79% 294B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 245B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 222B
A+
NOVARTIS AG Stock Novartis AG
+11.95% 215B
B-
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4886 Stock
  4. Ratings ASKA Pharmaceutical Holdings Co.,Ltd.